Robert V. Baumgartner, a director at Bio-Techne Corp, has reported a transaction involving the acquisition of 2,750 shares of the company's common stock. This transaction, dated October 29, 2026, underscores Baumgartner's continued investment in the company, which is significant for stakeholders monitoring insider activities.

Background

Bio-Techne Corp, incorporated in Minnesota, operates in the biological products industry. The company is known for its innovative solutions in life sciences, particularly in the development and manufacturing of high-quality biological products. The firm is listed under the ticker symbol TECH and has been actively filing with the SEC, including recent submissions that highlight its ongoing business activities.

What the Filing Says

According to the recent filing, Baumgartner acquired 2,750 shares at no cost, bringing his total ownership to 59,634 shares. The filing states, "Transaction Code: A," indicating an acquisition of shares. This level of insider ownership suggests confidence in the company's future performance.

Impact

This transaction may affect various stakeholders, including investors and analysts who track insider trading as a potential indicator of company performance. Baumgartner's actions could influence market perceptions of Bio-Techne Corp, especially among competitors and other industry players.

What's Next

The filing does not say what happens next.

Details of Derivative Holdings

In addition to the recent acquisition of shares, Baumgartner holds several stock options that provide him the right to purchase additional shares of Bio-Techne Corp. These options include various grants with different exercise prices and expiration dates. For instance, he has options to buy 12,500 shares at an exercise price of $31.26, which expire on October 26, 2027, and options for 7,592 shares at $44.96, expiring on October 25, 2028.

Other notable options include the right to purchase 8,044 shares at $50.41, expiring on October 24, 2029, and 6,028 shares at $63.92, expiring on October 29, 2030. These derivative holdings further demonstrate Baumgartner's significant stake in the company and his potential to influence its future through additional share acquisitions.

Ownership Structure

Following the recent transaction, Baumgartner's total ownership now stands at 59,634 shares of common stock, reflecting a direct ownership structure. This direct ownership indicates that he has full control over the shares and their associated voting rights, which could be pivotal in corporate governance matters.

Signature and Filing Details

The filing was signed by Andrew Nick, acting as Attorney-in-Fact for Robert V. Baumgartner, under a Power of Attorney previously filed. This adds a layer of legitimacy to the transaction, ensuring compliance with SEC regulations.

What the Filing Does Not Include

The filing does not provide insights into Baumgartner's future plans regarding his holdings or any potential strategies he may pursue in relation to Bio-Techne Corp. Additionally, there is no mention of the broader market context or how this transaction aligns with the company's strategic objectives.